60 Degrees Pharma Secures Exclusive Option for Tick-Borne Disease Treatment
The Nasdaq-listed biotech gains development rights to castanospermine through Florida State University agreement, broadening infectious disease portfolio.
60 Degrees Pharmaceuticals has secured an exclusive option agreement with Florida State University to develop castanospermine for tick-borne diseases, a move that expands the company's infectious disease pipeline.
Under the arrangement, 60 Degrees Pharma (Nasdaq: SXTP) gains exclusive rights to develop and commercialize the compound, which targets a category of illnesses transmitted by tick vectors. The agreement represents the biotech's latest addition to its pipeline focused on infectious disease indications.
Tick-borne diseases remain a significant public health concern, with incidence rates rising across endemic regions. The acquisition of development rights to castanospermine positions 60 Degrees Pharma to explore therapeutic applications in this underserved market segment. The compound's mechanism and prior research formed the basis for the university's decision to partner with the company.
The exclusive option structure allows 60 Degrees Pharma to evaluate the therapeutic potential of castanospermine before committing to full development. Terms of the agreement were not disclosed. Florida State University retains involvement through the collaboration framework, typical of academic-industry partnerships in drug development.
60 Degrees Pharma has built its portfolio around infectious disease treatments, positioning itself within a market focused on addressing gaps in current therapeutic options. The addition of tick-borne disease indication represents a strategic expansion of the company's existing platform.
The agreement underscores ongoing interest among biotech firms in addressing vector-borne pathogens, particularly as epidemiological patterns shift across North America and Europe.